A Study of Revumenib and Mezigdomide in People With Leukemia
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Mezigdomide
Related studies linked through entity extraction aliases.
Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Expanded Access for Mezigdomide
- Status
- AVAILABLE
- Phase
- N/A
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2